JPH04183371A - Bone-fortifying food, feed and pharmaceutical - Google Patents
Bone-fortifying food, feed and pharmaceuticalInfo
- Publication number
- JPH04183371A JPH04183371A JP2309504A JP30950490A JPH04183371A JP H04183371 A JPH04183371 A JP H04183371A JP 2309504 A JP2309504 A JP 2309504A JP 30950490 A JP30950490 A JP 30950490A JP H04183371 A JPH04183371 A JP H04183371A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- bone
- water
- whey protein
- whey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 20
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 53
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 51
- 235000021119 whey protein Nutrition 0.000 claims abstract description 43
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 15
- 108091005804 Peptidases Proteins 0.000 claims abstract description 12
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 12
- 102000035195 Peptidases Human genes 0.000 claims abstract description 8
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 21
- 238000005728 strengthening Methods 0.000 claims description 18
- 159000000007 calcium salts Chemical class 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 235000014106 fortified food Nutrition 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 12
- 239000005862 Whey Substances 0.000 abstract description 10
- 235000018102 proteins Nutrition 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 235000013336 milk Nutrition 0.000 abstract description 9
- 210000004080 milk Anatomy 0.000 abstract description 9
- 239000008267 milk Substances 0.000 abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 abstract description 5
- 239000005018 casein Substances 0.000 abstract description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 4
- 235000021240 caseins Nutrition 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 238000000502 dialysis Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000001223 reverse osmosis Methods 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000006227 byproduct Substances 0.000 abstract description 2
- 235000013351 cheese Nutrition 0.000 abstract description 2
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 238000006911 enzymatic reaction Methods 0.000 abstract description 2
- 229940108461 rennet Drugs 0.000 abstract description 2
- 108010058314 rennet Proteins 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract description 2
- 238000000108 ultra-filtration Methods 0.000 abstract description 2
- 235000019833 protease Nutrition 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229960005069 calcium Drugs 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 235000001465 calcium Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 229940036811 bone meal Drugs 0.000 description 2
- 239000002374 bone meal Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Fodder In General (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
生果上皇机里分団
本発明は、乳清蛋白の水可溶性画分または、その蛋白分
解酵素分解物の水可溶性百分を含有せしめてなる骨強化
食品、飼料または医薬に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention provides a bone-strengthening food, feed, or medicine containing a water-soluble fraction of whey protein or a water-soluble percentage of its proteolytic enzyme decomposition product. Regarding.
さらに、本発明は、水可溶性または蛋白分解酵素分解物
よりなる水可溶性画分に適当なカルシウム塩を併用せし
めてなる骨強化食品、飼料または医薬に関する。Furthermore, the present invention relates to bone-strengthening foods, feeds, or medicines made by combining a water-soluble fraction or a water-soluble fraction consisting of a proteolytic enzyme-degraded product with an appropriate calcium salt.
従来夏肢玉
近年、高齢化に伴い、骨粗鬆症、骨折および腰痛などの
各種骨疾患の患者が増加している。これらはカルシウム
の摂取不足、カルシウム吸収能の低下、活性化ビタミン
Ｄ３分泌の不足およびホルモンのアンバランスなどが原
因であるといわれている。In recent years, with the aging of the population, the number of patients with various bone diseases such as osteoporosis, fractures, and lower back pain has increased. These are said to be caused by insufficient calcium intake, reduced calcium absorption ability, insufficient secretion of activated vitamin D3, and hormonal imbalance.
現在カルシウムの補給を目的として炭酸カルシウム、乳
酸カルシウム、およびリン酸カルシウムなどのカルシウ
ム塩や牛骨粉、卵殻および魚骨粉などの天然カルシウム
剤が使われている。Currently, calcium salts such as calcium carbonate, calcium lactate, and calcium phosphate, and natural calcium agents such as beef bone meal, eggshell, and fish bone meal are used for calcium supplementation.
また、骨粗に症や、骨強化のための医薬とじては、ビタ
ミンＩα（ＯＨ）Ｄｚおよびカルシトニン製剤などがあ
る。In addition, medicines for osteoporosis and bone strengthening include vitamin Iα(OH)Dz and calcitonin preparations.
しかし、これらは医薬そのものであって、食品素材に使
う安全でしかも長期的にマイルドな条件で摂取して、骨
強化をする物質については知られていない。However, these are medicines themselves, and there is no knowledge of substances used in food materials that are safe and can be taken under mild conditions over a long period of time to strengthen bones.
日が” しようとじている課
乳は天然素材としてずくれているが、乳をそのまま食品
または医薬として摂取したとしても乳清蛋白およびペプ
チドを多量に摂取利用することかできない。Milk, which has been around for a long time, is considered a natural material, but even if milk is taken as a food or medicine, it is not possible to ingest and utilize large amounts of whey protein and peptides.
本発明は、このような従来の乳由来の乳清蛋白およびペ
プチドの利用ならびに骨強化を目的としてなされたもの
である。すなわち、本発明は、乳清蛋白及びペプチドを
多量に吸収することができ、骨を強化することのできる
骨強化食品、医薬及び飼料を提供することを課題とする
。The present invention was made with the aim of utilizing such conventional milk-derived whey proteins and peptides and strengthening bones. That is, an object of the present invention is to provide bone-strengthening foods, medicines, and feeds that can absorb large amounts of whey protein and peptides and can strengthen bones.
ｉ ° るための１
本発明者らは、乳清蛋白及びペプチドを吸収することが
でき、またカルシウムの吸収をも促進することのできる
食品、飼料及び医薬を、乳清から得ることについて検討
を行った。その結果、乳清の水可溶性画分あるいは、蛋
白分解酵素により加水分解して得られる水可溶性画分あ
るいはこれらの両分から逆浸透（ＲＯ）膜または電気透
析（ＥＤ）等により乳清由来の塩を除いた蛋白混合物は
、骨を強化する作用があり、さらにこれらに吸収性の良
いカルシウム剤を添加することによりカルシウム吸収を
一段と促進することができることを見出した。1. The present inventors have investigated the possibility of obtaining foods, feeds, and medicines from whey that can absorb whey proteins and peptides and also promote calcium absorption. went. As a result, the water-soluble fraction of whey, the water-soluble fraction obtained by hydrolysis with proteolytic enzymes, or both of these fractions is purified using a reverse osmosis (RO) membrane or electrodialysis (ED), etc. to extract whey-derived salts. It has been found that a protein mixture excluding the above has the effect of strengthening bones, and that calcium absorption can be further promoted by adding a highly absorbable calcium agent to the protein mixture.
そして、これらの知見に基づいて骨を強化する作用を有
する食品、医薬あるいは飼料を得るに至ったものである
。Based on these findings, we have now obtained foods, medicines, and feeds that have the effect of strengthening bones.
すなわち、本発明は、
（１）乳清蛋白の水可溶性画分を含有せしめてなる骨強
化食品、飼料または医薬。That is, the present invention provides: (1) A bone-strengthening food, feed, or medicine containing a water-soluble fraction of whey protein.
（２）乳清蛋白の分子量４５，０００〜１０，０００で
等電点がＰＩ３〜８の水可溶性画分を含有する骨強化食
品、飼料または医薬。(2) A bone-strengthening food, feed, or medicine containing a water-soluble fraction of whey protein with a molecular weight of 45,000 to 10,000 and an isoelectric point of PI 3 to 8.
（３）乳清蛋白の水可溶性画分を蛋白分解酵素で酵素分
解し、得られる分子量２０．０００〜３００の蛋白分解
酵素分解物よりなる水可溶性画分を含有せしめてなる骨
強化食品、飼料または医薬。(3) Bone-strengthening food and feed containing a water-soluble fraction consisting of a proteolytic enzyme decomposition product with a molecular weight of 20,000 to 300 obtained by enzymatically decomposing the water-soluble fraction of whey protein with a protease. Or medicine.
（４） 乳清蛋白よりなる水可溶性画分または、蛋白
分解酵素分解物よりなる水可溶性画分に適当なカルシウ
ム塩とともに含有せしめてなる上記（１）〜（３）のい
ずれかに記載の骨強化食品、飼料または医薬。(4) The bone according to any one of (1) to (3) above, which is obtained by containing a water-soluble fraction consisting of whey protein or a water-soluble fraction consisting of a proteolytic enzyme decomposition product together with an appropriate calcium salt. Fortified food, feed or medicine.
本発明における原料の乳は、牛乳、人乳、ヤギ乳、羊乳
などがあげられる。Examples of the raw material milk in the present invention include cow's milk, human milk, goat's milk, and sheep's milk.
乳清は、乳または脱脂乳に酸を加えるかまたは、レンネ
ットを作用させて生ずる凝固物を除いた透明な黄緑色の
液体であって、チーズまたはカゼイン製造の副産物とし
て得られる。Whey is a clear yellow-green liquid obtained by adding acid to milk or skimmed milk or removing the coagulum produced by the action of rennet, and is obtained as a by-product of cheese or casein production.
本発明における乳清蛋白は、この乳清を限外濾過、逆浸
透法、クロマトグラフィー、透析などにより得られる水
可溶性の蛋白である。特に分子量ｔｏ 、 ｏｏｏ〜４
５．０００で等電点がＰＩ３〜８の乳清蛋白の水可溶性
画分は望ましい。The whey protein in the present invention is a water-soluble protein obtained from whey by ultrafiltration, reverse osmosis, chromatography, dialysis, etc. Especially molecular weight to, ooo~4
A water soluble fraction of whey protein with an isoelectric point of PI 3-8 at 5.000 is desirable.
本発明ではこの両分をそのまま、または脱塩濃縮したり
あるいは乾燥したりして使用する。 蛋白分解酵素によ
る酵素分解を行う場合には、この溶液あるいは懸濁液に
蛋白分解酵素を添加して酵素分解する。蛋白分解酵素に
は、ペプシン、トリプシン、キモトリプシン等を使用す
ることができる。酵素反応は、ｆ４液または懸′／＠液
を使用する酵素の至適ｐＨ１至適温度になるように調製
し、酵素を添加し、数１０分〜数時間放置乃至撹拌を行
うことによってなされる。このようにすると、分子量２
０ 、０００〜３００程度の蛋白分解酵素分解物を得る
ことができる。この蛋白分解酵素分解物は乳清蛋白また
はペプチドよりなるものである。In the present invention, these two components are used as they are, or after being desalted and concentrated or dried. When enzymatically decomposing with a proteolytic enzyme, the protease is added to this solution or suspension for enzymatic decomposition. Pepsin, trypsin, chymotrypsin, etc. can be used as the protease. Enzyme reactions are carried out by adjusting the f4 solution or suspension solution to the optimum pH and temperature of the enzyme used, adding the enzyme, and allowing it to stand or stir for several tens of minutes to several hours. . In this way, the molecular weight is 2
A protease-degraded product of about 0.000 to 300% can be obtained. This protease-digested product consists of whey protein or peptides.
本発明における水可溶性画分は、吸収性のよいカルシウ
ム塩を添加することが望ましい。この時には塩化カルシ
ウム、炭酸カルシウム、乳酸カルシウム、卵殻あるいは
牛乳由来のカルシウム等の吸収性のよいカルシウム塩あ
るいはその含有物を添加するとよ（・。It is desirable that a calcium salt with good absorption is added to the water-soluble fraction in the present invention. At this time, it is recommended to add highly absorbable calcium salts or substances containing them, such as calcium chloride, calcium carbonate, calcium lactate, calcium derived from eggshells or milk.
本発明の食品、飼料あるいは医薬は、これらの水可溶性
画分、あるいはこれらの画分の脱塩画分さらにこの脱塩
画分の吸収性のよいカルシウム塩を添加してなるもの等
が含有するものである。The food, feed, or medicine of the present invention contains these water-soluble fractions, or desalted fractions of these fractions, and a product obtained by adding a highly absorbable calcium salt of this desalted fraction. It is something.
食品の例を挙げると、飲料、ゼリー、錠剤、パン、麺、
スープ、ソーセージ等があり、飼料には、飼料添加物、
その他の飼料が、さらに医薬として経口的に投与できる
錠剤、顆粒剤、液剤等があげられる。これらの医薬は経
口的に投与され、骨粗■症（オステオポローゼ）の予防
あるいは治療に用いられる。投与量は成人、約４０００
〜８０００■／１日を数回に分けて投与することが望ま
しい。また、前記画分は元来、乳の成分であって、ラッ
トによる動物試験でも急性毒性は認められなかった。Examples of foods include beverages, jelly, tablets, bread, noodles,
There are soups, sausages, etc., and the feed includes feed additives,
Other feeds include tablets, granules, liquid preparations, etc. that can be orally administered as medicines. These drugs are administered orally and are used to prevent or treat osteoporosis. Dosage for adults: approximately 4000
It is desirable to divide the dose into several doses at ~8000 μ/day. Furthermore, the fraction is originally a component of milk, and no acute toxicity was observed in animal tests using rats.
次に本発明の乳清ペプチド及び蛋白の製造法を実施例を
あげて説明する。Next, the method for producing whey peptides and proteins of the present invention will be explained with reference to Examples.
実施例１
乳清蛋白（ＷＰ−Ｎ）の調製法
脱脂乳１００ｆに６Ｎ塩酸を滴下して、ｐ）ｌ ４．７
にじた。１時間放置後、沈澱したカゼインを遠心して除
き乳清を得た。Example 1 Preparation method of whey protein (WP-N) 6N hydrochloric acid was added dropwise to 100f of skim milk, p)l 4.7
Rainbow. After standing for 1 hour, precipitated casein was removed by centrifugation to obtain whey.
この乳清を膜面積が０．７２ｒｒｆのＤＯ−社製のｔｌ
Ｆ膜ＧＲ６１ＰＰ （分画分子量２万ダルトン）を用い
て濃縮した。This whey was mixed with a tl manufactured by DO- Co., Ltd. with a membrane area of 0.72rrf.
It was concentrated using F membrane GR61PP (molecular weight cut off: 20,000 Daltons).
さらにダイアフィルトレージョンにより乳清蛋白質を精
製した。４．３Ｃの精製液を蒸留水にて十分に透析した
。透析後、凍結乾燥して乳清蛋白画分（−Ｐ）を含む粉
末４６８ｇを得た。Whey protein was further purified by diafiltration. The purified solution of 4.3C was thoroughly dialyzed against distilled water. After dialysis, 468 g of powder containing whey protein fraction (-P) was obtained by freeze-drying.
−Ｐを９抛ｍ Ｘ ５００ｍｍのＧ−１００カラムにか
けこれを分画し、分画分子量１０，０００〜４５，００
０の乳清蛋白（ＷＰ−Ｎ） １８０ｇを得た。-P was applied to a G-100 column of 9 mm x 500 mm to fractionate it, and the molecular weight cut off was 10,000 to 45,00.
180 g of whey protein (WP-N) was obtained.
実施例２
乳清蛋白トリプシン分解物（ＷＰ−Ｔ）の調製実施例１
に記載した方法で、得られた乳清蛋白（ＭＰ−Ｎ）２０
０ｇを４．５１の蒸留水に溶解した。Example 2 Preparation of whey protein tryptic digest (WP-T) Example 1
Whey protein (MP-N) obtained by the method described in
0 g was dissolved in 4.51 g of distilled water.
これに４ｇのトリプシンを添加し、３７°Ｃで５時間反
応させて、乳清蛋白トリプシン分解物を生成セしめた。4 g of trypsin was added to this and reacted at 37°C for 5 hours to produce a whey protein tryptic decomposition product.
その後、８４°Ｃ５分間保持して酵素を失活せしめ、凍
結乾燥し、乳清蛋白トリプシン分解物（ＷＰ−Ｔ）を含
む粉末２９２ｇを得た―この分子量は２０．０００〜３
００であった。Thereafter, the enzyme was inactivated by holding at 84°C for 5 minutes and freeze-dried to obtain 292g of powder containing whey protein tryptic decomposition product (WP-T), which had a molecular weight of 20.000 to 3.
It was 00.
実施例３
乳清蛋白（ＷＰ−Ｎ）および乳清蛋白トリプシン分解物
（ＷＰ−Ｔ）の骨強化効果
（１）被験試料を添加したラット飼料組成試験に使用し
た飼料の組成を第１表及び第２表に示す。Example 3 Bone strengthening effect of whey protein (WP-N) and whey protein tryptic digest (WP-T) (1) Rat feed composition to which the test sample was added The composition of the feed used in the test is shown in Table 1 and Shown in Table 2.
第１表 飼料基本組成（ｇ／１００ｇ）第２表 各群の
飼料タンパク及びミネラル組成（ｇ／１００ｇ）
実施例１および２で得られた畦、ＷＰ−Ｎ、 ＷＰ−Ｔ
を第２表に示すように飼料にそれぞれ別々に１．０９％
、１％、１％添加し、カゼインで飼料中蛋白量が２０％
になるよう調整した。飼料中力ルシウム量は、すべての
群で飼料１００ｇあたりのカルシウム量が３００■とな
るよう炭酸カルシウムで調整した。またリン４００■、
カリウム３５０ｍｇ、マグ７シウム８０■ナトリウム１
００■になるように調整した。Table 1: Basic feed composition (g/100g) Table 2: Feed protein and mineral composition of each group (g/100g) Ridges obtained in Examples 1 and 2, WP-N, WP-T
1.09% of each separately in the feed as shown in Table 2.
, 1%, 1% added, casein increases protein content in feed by 20%
I adjusted it so that The amount of lucium in the feed was adjusted with calcium carbonate so that the amount of calcium per 100 g of feed was 300 μl in all groups. Also, 400 phosphorus,
Potassium 350mg, Mag 7Sium 80■ Sodium 1
It was adjusted to be 00■.
（２）使用動物及び骨粗鬆症モデル動物の作成動物は５
週齢のＳＤ系雌性ラットを用いた。骨粗■症モデルラッ
トは、１週間予備飼育した後に卵巣摘出手術を施し低カ
ルシウム食で１力月間飼育することにより作成した。１
試験群各７匹で試験を行った。(2) Animals used and animals used to create osteoporosis model animals are 5.
Week-old SD female rats were used. Osteoporosis model rats were prepared by preliminarily rearing them for one week, then undergoing ovariectomy, and then rearing them on a low-calcium diet for one month. 1
The test was conducted with 7 animals in each test group.
（３）骨強化試験
骨粗Ｎ症モデルラントを上記被験飼料で１力月間飼育し
た後、大腿骨を摘出し骨強度を破断特性測定装置で測定
した。(3) Bone Strengthening Test After the osteoporosis N model runts were fed with the above test feed for one month, the femurs were removed and the bone strength was measured using a fracture characteristic measuring device.
（４）試験結果
試験結果を第１図及び第２図に示す。第１図に示したよ
うに骨破断力は、対照群に比べ乳清蛋白（ＷＰ−Ｎ）を
加えた群および乳清蛋白トリプシン分解物（ＷＰ−Ｔ）
を加えた群で顕著に高い値を示した。第２図に示した骨
破断エネルギーも対照群や低カルシウム群に比べ、ＭＰ
−Ｎと−Ｐ−Ｔを加えた群で顕著に高い値を示した。し
かもジャム ＣａＣＯ３添加群よりも高い値を示した。(4) Test results The test results are shown in Figures 1 and 2. As shown in Figure 1, the bone breaking force was higher in the whey protein (WP-N) group and in the whey protein tryptic digest (WP-T) than in the control group.
A significantly higher value was observed in the group in which . The bone fracture energy shown in Figure 2 was also lower than that of the control group and the low calcium group.
The group containing -N and -PT showed a significantly higher value. Moreover, the value was higher than that of the jam CaCO3 addition group.
このことから、乳清蛋白（ＷＰ−Ｎ）および乳清蛋白ト
リプシン分解物（ＷＰ−Ｔ）に骨強化作用があることが
分かった。From this, it was found that whey protein (WP-N) and whey protein tryptic decomposition product (WP-T) have a bone strengthening effect.
本発明の食品、飼料あるいは医薬について実施例をあげ
て具体的に示す。The food, feed, or medicine of the present invention will be specifically illustrated by giving examples.
実施例４ （ＷＰ−Ｎまたは−Ｐ−Ｔ入り飲料）上
記配合比によって通常の製造法にて果汁飲料を製造した
。Example 4 (WP-N or -PT-containing beverage) A fruit juice beverage was produced using the above blending ratio and a normal production method.
実施例５ （ＷＰ−ＮまたはＭＰ−Ｔ入りゼリー）
上記配合比によって通常の製造法にてゼリーを製造した
。Example 5 (jelly containing WP-N or MP-T)
A jelly was manufactured using the above-mentioned blending ratio using a conventional manufacturing method.
実施例６ （ＭＰ−Ｎまたは−Ｐ−Ｔ入り錠剤）上
記配合比によって通常の製造法にて錠剤を製造した。得
られた錠剤は、カルシウム及び蛋白補強の栄養剤として
１日５〜６錠あるいは骨粗鬆症の予防または治療に１日
６〜１０錠投与することができる。Example 6 (Tablets containing MP-N or -PT) Tablets were manufactured using the above-mentioned compounding ratio and a conventional manufacturing method. The obtained tablets can be administered 5 to 6 tablets per day as a nutritional supplement for calcium and protein supplementation, or 6 to 10 tablets per day for the prevention or treatment of osteoporosis.
実施例７ ［イヌ飼育用飼料（ドッグフード）］バー
ム油 ２
ビタミン混合物＋１ ２
ミネラル混合物２ン ９
セルロース ２
ビタミンＡ １５００ ｒ［ｌビタミンＤ：
ｌ ３００ ＩｌｌビタミンＥ
６．８ Ｍ
ビタミンＢ、 ０．９■
ビタミン８２ ０．４■
コリン ２００．０■
ビオチン ２４．４８ｇ
イノシトール ５０．０ ｍｇ
イアシン １０．５
ショ糖で２ｇとした。Example 7 [Dog feed (dog food)] Balm oil 2 Vitamin mixture + 1 2 Mineral mixture 2 9 Cellulose 2 Vitamin A 1500 r[l Vitamin D:
l 300 Ill Vitamin E
6.8 M Vitamin B, 0.9 ■ Vitamin 82 0.4 ■ Choline 200.0 ■ Biotin 24.48 g Inositol 50.0 mg Iacin 10.5 It was made into 2 g with sucrose.
２）ミネラル混合物
上記イヌ飼育用基礎飼料１００ｇ中に上記配合量でビタ
ミン混合物及びミネラル混合物を加え通常の製造法にて
イヌ飼育用飼料を製造した。2) Mineral mixture A vitamin mixture and a mineral mixture were added in the above amounts to 100 g of the basic feed for dogs, and a feed for dogs was produced by a conventional manufacturing method.
主班皇蓋果
本発明の骨強化食品、飼料、医薬は、骨を強化する作用
があることから健康食品あるいは各種の骨関節疾患、特
に骨粗髭症の予防あるいは治療に有用である。また飼料
としても有用なものとなる。Since the bone-strengthening foods, feeds, and medicines of the present invention have a bone-strengthening effect, they are useful as health foods or in the prevention or treatment of various bone and joint diseases, particularly osteoporosis. It is also useful as feed.
第１図及び第２図は実施例３の骨強化試験の結果をそれ
ぞれ示す。
ジャム 対照 ＷＰ ＷＰ−Ｎ ＷＰ−Ｔ
第１ｒＡ1 and 2 show the results of the bone reinforcement test of Example 3, respectively. Jam Control WP WP-N WP-T
1st rA
Claims (4)
化食品、飼料または医薬。(1) A bone-strengthening food, feed, or medicine containing a water-soluble fraction of whey protein.
等電点がＰＩ３〜８の水可溶性画分を含有する骨強化食
品、飼料または医薬。(2) A bone-strengthening food, feed, or medicine containing a water-soluble fraction of whey protein with a molecular weight of 45,000 to 10,000 and an isoelectric point of PI 3 to 8.
解し、得られる分子量２０，０００〜３００の蛋白分解
酵素分解物よりなる水可溶性画分を含有せしめてなる骨
強化食品、飼料または医薬。(3) Bone-strengthening food and feed containing a water-soluble fraction consisting of a proteolytic enzymatic decomposition product with a molecular weight of 20,000 to 300 obtained by enzymatically decomposing the water-soluble fraction of whey protein with a protease. Or medicine.
解物よりなる水可溶性画分に適当なカルシウム塩ととも
に含有せしめてなる請求項（１）〜（３）のいずれかに
記載の骨強化食品、飼料または医薬。(4) The bone according to any one of claims (1) to (3), which is obtained by containing a water-soluble fraction of whey protein or a water-soluble fraction consisting of a proteolytic enzyme decomposition product together with an appropriate calcium salt. Fortified food, feed or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30950490A JP3160862B2 (en) | 1990-11-15 | 1990-11-15 | Bone-fortified foods, feeds and pharmaceuticals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30950490A JP3160862B2 (en) | 1990-11-15 | 1990-11-15 | Bone-fortified foods, feeds and pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04183371A true JPH04183371A (en) | 1992-06-30 |
| JP3160862B2 JP3160862B2 (en) | 2001-04-25 |
Family
ID=17993794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30950490A Expired - Lifetime JP3160862B2 (en) | 1990-11-15 | 1990-11-15 | Bone-fortified foods, feeds and pharmaceuticals |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3160862B2 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0573668A1 (en) * | 1991-12-26 | 1993-12-15 | Snow Brand Milk Products Co., Ltd. | Bone reinforcing factor, and food and drink containing said factor |
| EP0786473A2 (en) | 1996-01-23 | 1997-07-30 | Snow Brand Milk Products Co., Ltd. | Basic protein composition, basic peptide composition and application thereof |
| EP0787499A1 (en) | 1996-02-08 | 1997-08-06 | Snow Brand Milk Products Co., Ltd. | Kininogen for promoting bone formation and inhibiting bone resorption |
| EP0791601A3 (en) * | 1996-02-23 | 1998-11-25 | Snow Brand Milk Products Co., Ltd. | An agent promoting bone formation and inhibiting bone resorption |
| WO2000049885A1 (en) * | 1999-02-25 | 2000-08-31 | Societe Des Produits Nestle S.A. | Milk protein hydrolysate for addressing a bone or dental disorder |
| US6649590B2 (en) | 2000-06-09 | 2003-11-18 | Snow Brand Milk Products Co., Ltd. | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof |
| JP2007210995A (en) * | 1994-05-24 | 2007-08-23 | Paolo Minoia | Pharmaceutical composition containing opiate antagonist and calcium salt and their use for treatment of endorphin-mediated pathology |
| CN102617702A (en) * | 2012-03-09 | 2012-08-01 | 姜浩奎 | Production method of peptidoglycan |
| US8853232B2 (en) | 2007-03-29 | 2014-10-07 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| US8916706B2 (en) | 2008-02-06 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
| US8916581B2 (en) | 2005-05-25 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
| US9102680B2 (en) | 2007-03-29 | 2015-08-11 | Wyeth Llc | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
| US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
| US9597327B2 (en) | 2005-05-25 | 2017-03-21 | Progenics Pharmaceuticals, Inc. | Synthesis of (R)-N-methylnaltrexone |
| US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY160058A (en) | 2007-11-01 | 2017-02-15 | Megmilk Snow Brand Co Ltd | Bone-reinforcing food material |
| JPWO2009057282A1 (en) | 2007-11-01 | 2011-03-10 | 雪印乳業株式会社 | Food material for suppressing bone resorption |
| KR20100100831A (en) | 2007-11-01 | 2010-09-15 | 유키지루시 뉴교 가부시키가이샤 | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast |
| KR20100100845A (en) | 2007-11-01 | 2010-09-15 | 유키지루시 뉴교 가부시키가이샤 | Food material for inhibiting the formation of osteoclast |
-
1990
- 1990-11-15 JP JP30950490A patent/JP3160862B2/en not_active Expired - Lifetime
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0573668A4 (en) * | 1991-12-26 | 1995-11-02 | Snow Brand Milk Products Co Ltd | Bone reinforcing factor, and food and drink containing said factor |
| US5654019A (en) * | 1991-12-26 | 1997-08-05 | Snow Brand Milk Products Co., Ltd. | Bone enhancing factors from whey and compositions containing the same |
| EP0573668A1 (en) * | 1991-12-26 | 1993-12-15 | Snow Brand Milk Products Co., Ltd. | Bone reinforcing factor, and food and drink containing said factor |
| JP2007210995A (en) * | 1994-05-24 | 2007-08-23 | Paolo Minoia | Pharmaceutical composition containing opiate antagonist and calcium salt and their use for treatment of endorphin-mediated pathology |
| EP0786473A2 (en) | 1996-01-23 | 1997-07-30 | Snow Brand Milk Products Co., Ltd. | Basic protein composition, basic peptide composition and application thereof |
| US5976597A (en) * | 1996-01-23 | 1999-11-02 | Fujino Patent Attorney | Basic protein composition, basic peptide composition and application thereof |
| EP0787499A1 (en) | 1996-02-08 | 1997-08-06 | Snow Brand Milk Products Co., Ltd. | Kininogen for promoting bone formation and inhibiting bone resorption |
| US5885964A (en) * | 1996-02-08 | 1999-03-23 | Snow Brand Milk Products Co., Ltd. | Kininogen agent promoting bone formation and inhibiting bone resorption |
| EP0791601A3 (en) * | 1996-02-23 | 1998-11-25 | Snow Brand Milk Products Co., Ltd. | An agent promoting bone formation and inhibiting bone resorption |
| WO2000049885A1 (en) * | 1999-02-25 | 2000-08-31 | Societe Des Produits Nestle S.A. | Milk protein hydrolysate for addressing a bone or dental disorder |
| US6649590B2 (en) | 2000-06-09 | 2003-11-18 | Snow Brand Milk Products Co., Ltd. | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof |
| US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
| US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
| US9597327B2 (en) | 2005-05-25 | 2017-03-21 | Progenics Pharmaceuticals, Inc. | Synthesis of (R)-N-methylnaltrexone |
| US8916581B2 (en) | 2005-05-25 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
| US8853232B2 (en) | 2007-03-29 | 2014-10-07 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| US9102680B2 (en) | 2007-03-29 | 2015-08-11 | Wyeth Llc | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
| US9879024B2 (en) | 2007-03-29 | 2018-01-30 | Progenics Pharmaceuticals., Inc. | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
| US8916706B2 (en) | 2008-02-06 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
| US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
| US9492445B2 (en) | 2008-09-30 | 2016-11-15 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
| US9724343B2 (en) | 2008-09-30 | 2017-08-08 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
| CN102617702A (en) * | 2012-03-09 | 2012-08-01 | 姜浩奎 | Production method of peptidoglycan |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3160862B2 (en) | 2001-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2974604B2 (en) | Basic protein composition, basic peptide composition and use thereof | |
| JPH04183371A (en) | Bone-fortifying food, feed and pharmaceutical | |
| JP3018313B2 (en) | Bone formation promotion and bone resorption inhibitor | |
| CA2349980C (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| JP2947484B2 (en) | Bone-fortified food, feed or osteoarthritis prophylactic or therapeutic drug | |
| JP3092874B2 (en) | Whey-derived osteoblast-proliferating and bone-enhancing fraction and bone-enhanced food, feed, and pharmaceuticals containing the fraction | |
| JP2001346519A (en) | Method for producing fraction containing high content of milk basic cystatin and decomposed product thereof | |
| EP2208734B1 (en) | Food material for inhibiting the formation of osteoclast | |
| US5654019A (en) | Bone enhancing factors from whey and compositions containing the same | |
| JP5357042B2 (en) | Bone strengthening food material | |
| AU2008320271B2 (en) | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast | |
| JPH0453471A (en) | Bone-enriched food, feed and medicine | |
| AU784087B2 (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| JP3742523B2 (en) | Polymeric calcium phosphopeptide complex | |
| JP2002000193A (en) | Method for producing fraction having high milk-derived basic cystatin content and cleavaged product thereof | |
| JP3604159B2 (en) | Whey-derived osteoblast proliferation-promoting and bone-strengthening factor and bone-strengthened food, medicine and feed containing the factor | |
| KR101441728B1 (en) | Food material for inhibiting bone resorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080223 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090223 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090223 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100223 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110223 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110223 Year of fee payment: 10 |